Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study
Por:
Martinez, E, Garin, O, Pardo, Y, Fernandez, P, Guix, B, Gutierrez, C, Boladeras, A, Ferrer, F, Hernandez, T, Ayala, A, Egiguren, M, Fernandez, G, Munoz, V, Macias, V, Pera, J, Pont, A, Ferrer, M, Guedea, F, Sancho, G, Palou J., Multicentric Spanish Grp Clinicall
Publicada:
1 ene 2021
Resumen:
Purpose: Brachytherapy (BT) and external beam radiation therapy (EBRT) are effective treatments for high-risk prostate cancer (PCa). However, the impact of these treatments on health-related quality of life (HRQL) remains unclear. In this study, we compared EBRT alone with EBRT plus a boost with high-dose rate (HDR)-BT to determine the impact on HRQL in patients with high-risk PCa.
Material and methods: Prospective, multicenter study comparing patients with high-risk PCa treated with EBRT alone or EBRT + HDR-BT from 2004 to 2006. HRQL was assessed at baseline (pre-treatment) and periodically over the 5-year follow-up, using the SF-36 (v.2), EPIC, and FACT-G and FACT-P questionnaires.
Results: A total of 129 patients were included in the study, of these, 41 received EBRT alone and 88 EBRT + HDR-BT. All patients received hormonotherapy. Baseline clinical characteristics were similar, except for a slightly higher mean number of comorbidities in the EBRT group. During follow-up, the only significant between-group difference was a greater worsening on EPIC hormonal domain in the EBRT alone group (p = 0.028). There were no significant differences in time and interaction of treatment in SF-36, and FACT-G and FACT-P questionnaires or EPIC urinary incontinence, urinary irritative-obstructive, and bowel and sexual domains over the 5-year follow-up. Oncological outcomes were similar in both groups.
Conclusions: After five years of follow-up, EBRT alone or combined with HDR-BT boost had a similar impact on HRQL in patients with high-risk localized PCa. However, patients in the EBRT alone group experienced greater worsening of hormonal domain according to EPIC questionnaire.
Filiaciones:
Martinez, E:
Inst Catala Oncol, Serv Oncol Radioterap, Barcelona, Spain
Inst Mexicano Seguro Social IMSS, Ctr Med Nacl Occidente CMNO, Unidad Med Alta Especialidad UMAE, Dept Radio Oncol, Mexico City, DF, Mexico
Garin, O:
IMIM Hosp del Mar, Unidad Invest Serv Sanitarios, Barcelona, Spain
CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain
Pompeu Fabra Univ UPF, Barcelona, Spain
Pardo, Y:
IMIM Hosp del Mar, Unidad Invest Serv Sanitarios, Barcelona, Spain
CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain
Univ Autonoma Barcelona, Bellaterra, Spain
Fernandez, P:
Inst Oncol Guipuzkoa, Serv Oncel Radioterap, San Sebastian, Spain
Guix, B:
Inst Med Oncoradioterapia, Fdn IMOR, Barcelona, Spain
Gutierrez, C:
Inst Catala Oncol, Serv Oncol Radioterap, Barcelona, Spain
Boladeras, A:
Inst Catala Oncol, Serv Oncol Radioterap, Barcelona, Spain
Ferrer, F:
Inst Catala Oncol, Serv Oncol Radioterap, Barcelona, Spain
Hernandez, T:
Inst Catala Oncol, Serv Oncol Radioterap, Barcelona, Spain
Ayala, A:
Inst Oncol Guipuzkoa, Serv Oncel Radioterap, San Sebastian, Spain
Egiguren, M:
Inst Oncol Guipuzkoa, Serv Oncel Radioterap, San Sebastian, Spain
Fernandez, G:
Hosp Univ Cent Asturias, Serv Oncol Radioterap, Oviedo, Spain
Munoz, V:
Hosp Meixoeiro, Serv Oncol Radioterap, Vigo, Spain
Macias, V:
Hosp Univ & Politecn La Fe, Serv Oncol Radioterap, Valencia, Spain
Hosp Univ Gen Catalunya Quiron Salut, Barcelona, Spain
Pera, J:
Inst Catala Oncol, Serv Oncol Radioterap, Barcelona, Spain
Pont, A:
IMIM Hosp del Mar, Unidad Invest Serv Sanitarios, Barcelona, Spain
CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain
Ferrer, M:
IMIM Hosp del Mar, Unidad Invest Serv Sanitarios, Barcelona, Spain
CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain
Univ Autonoma Barcelona, Bellaterra, Spain
Guedea, F:
Inst Catala Oncol, Serv Oncol Radioterap, Barcelona, Spain
Sancho, G:
Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
Palou J.:
Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
Green Published, gold
|